Tisch Cancer Institute at Mount Sinai


 

ASH 2021 Rationale for and Results of a Phase I Study of the TGF-β 1/3 Inhibitor AVID200 in Subjects with MF

52 views
December 17, 2021
Comments 0
Login to view comments. Click here to Login